 SAN DIEGO, May 26, 2021 PRNewswire -- Kintara Therapeutics, Inc. Nasdaq: KTRA Kintara or the Company, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research GCAR registrational Phase 23 clinical trial for glioblastoma multiforme GBM has been activated in 15 U.S. sites as of May 14, 2021. The trial, titled GBM AGILE Glioblastoma Adaptive Global Innovative Learning Environment, is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. 